Spruce Biosciences, Inc. announced its financial results for Q2 2023 and provided updates on its Phase 2 clinical trial for the treatment of polycystic ovary syndrome (PCOS). Interim data from the trial showed positive results and support for the efficacy of the product candidate tildacerfont.